{"id":4244,"date":"2018-05-04T10:06:49","date_gmt":"2018-05-04T14:06:49","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4244"},"modified":"2018-05-04T10:06:49","modified_gmt":"2018-05-04T14:06:49","slug":"abpro-corporation-ipo-preview-abp","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/abpro-corporation-ipo-preview-abp\/","title":{"rendered":"Abpro Corporation #IPO Preview ($ABP)"},"content":{"rendered":"

\"abp\"<\/a><\/p>\n

Company: Abpro Corporation<\/strong>
\nSymbol: ABP
\nDescription: They are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.
\nTrade Date: 5\/11
\nShares: 4 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): UBS Investment Bank, Wells Fargo Securities, Nomura, Oppenheimer & Co.
\nTerms Added: 5-2-18<\/p>\n

Link to Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>:\u00a0They are initially focused on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. Their two lead product candidates,\u00a0ABP-100\u00a0and\u00a0ABP-201,\u00a0feature their next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target.\u00a0They plan initially to develop\u00a0ABP-100\u00a0for difficult to treat HER2+ solid tumors, focusing on orphan indications.\u00a0ABP-201\u00a0is designed to block blood vessel formation and normalize damaged vessels through\u00a0co-targeting\u00a0vascular endothelial growth factor, or VEGF, and\u00a0angiopoietin-2,\u00a0or\u00a0ANG-2.\u00a0They plan to develop\u00a0ABP-201\u00a0to treat vascular diseases of the eye, focusing on diabetic macular edema, or DME. They have exclusive licenses with worldwide commercialization rights to both\u00a0ABP-100\u00a0and\u00a0ABP-201,\u00a0and expect to initiate clinical trials for\u00a0ABP-100\u00a0in the first half of 2019 and for\u00a0ABP-201\u00a0in the second half of 2019. DiversImmune\u00a0is their antibody discovery platform that rapidly generates a diverse collection of proprietary antibodies against both clinically validated and novel targets that have been traditionally difficult to access. MultiMab\u00a0is their engineering platform that provides them with the flexibility to combine these antibody building blocks in different combinations and orientations to rapidly create \u201cfit for purpose\u201d novel\u00a0full-length\u00a0multi-specific antibody constructs. In contrast to single-format bispecific antibody platforms that are only able to provide a single solution to different biological problems, their platform enables them to design a diverse suite of full-length multi-specific antibody formats to address new problems in medicine.<\/p>\n

\"ABP.Candidates\"<\/a><\/p>\n

 <\/p>\n

License and Collaboration: <\/strong>They\u00a0are developing\u00a0ABP-100\u00a0in collaboration with Memorial Sloan Kettering Cancer Center, or MSK, and have an exclusive license to worldwide commercialization rights. Additionally, they\u00a0are developing ABP-201 with MedImmune Limited, or MedImmune, a subsidiary of AstraZeneca plc, and have an exclusive license to worldwide commercialization rights.<\/p>\n

Insider Buying:\u00a0<\/strong>Certain of their\u00a0existing stockholders have indicated an interest in purchasing an aggregate of up to and no more than $28.0\u00a0million in shares of their\u00a0common stock in this offering at the initial public offering price.<\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Abpro Corporation Symbol: ABP Description: They are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. Trade Date: 5\/11 Shares: 4 million Price Range: $14.00-$16.00 Underwriter(s): UBS Investment Bank, Wells Fargo Securities, Nomura, Oppenheimer & Co. Terms Added: 5-2-18 Link to Prospectus Link[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1504],"class_list":["post-4244","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-abp"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4244"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4244\/revisions"}],"predecessor-version":[{"id":4247,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4244\/revisions\/4247"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}